Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opiate analgesics

Executive Summary

FDA's Anesthetic & Life Support Drugs Advisory Committee will discuss the benefits and risks of the medical use of opiate analgesics in pediatric patients and patients with chronic pain of nonmalignant etiology Sept. 13 and 14. The committee will also address concerns regarding abuse potential, diversion and increase of addiction to modified release opiate analgesics. Purdue Pharma has developed an education program to prevent abuse of its controlled-release oxycodone product OxyContin. The meeting will begin at 8 a.m. both days at the University of Maryland-Shady Grove. An advisory committee meeting on the topics had been scheduled for June 14-15
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS038187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel